ArticleFuture oncology (London, England)2024

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.

Junsik Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.